KDR and neoplasm: Similarly, Kunkel et al. reported that inhibition of neo-angiogenesis by systemic treatment with an anti-VEGFR2 specific monoclonal antibody decreased microvessel density and tumor cell proliferation, increased apoptosis and inhibited overall tumor growth [3].